Merck & Co Inc
NYSE:MRK
Merck & Co Inc
NYSE:MRK
Price:
130.99 USD
-0.15%
Market Closed
Updated:
May 21, 2024
P/S
Price to Sales
Price to Sales
5.4
Current
4.4
Median
2.5
Industry
Higher
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=5.4
Market Cap
/
331.8B
Revenue
61.4B
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Merck & Co Inc
NYSE:MRK
|
331.8B USD | 5.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
744.3B USD | 20.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364.1B USD | 4.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.5B GBP | 5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 3.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 3.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | 2.9 | |
| FR |
|
Sanofi SA
PAR:SAN
|
111.8B EUR | 1.6 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
5.1
2-Years Forward
P/S
4.8
3-Years Forward
P/S
4.6
You don't have any saved screeners yet
